267 related articles for article (PubMed ID: 15215171)
1. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.
Iqbal J; Sanger WG; Horsman DE; Rosenwald A; Pickering DL; Dave B; Dave S; Xiao L; Cao K; Zhu Q; Sherman S; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Ott G; Müller-Hermelink HK; Delabie J; Braziel RM; Jaffe ES; Campo E; Lynch JC; Connors JM; Vose JM; Armitage JO; Grogan TM; Staudt LM; Chan WC
Am J Pathol; 2004 Jul; 165(1):159-66. PubMed ID: 15215171
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma.
Hallack Neto AE; Siqueira SA; Dulley FL; Chauobah A; Belesso M; Saboia R; Ruiz MA; Chamone DA; Pereira J
Sao Paulo Med J; 2010 Jan; 128(1):14-7. PubMed ID: 20512275
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases.
Sugitani A; Fukuhara S; Shibata M; Ichihara R; Furukawa H; Maeshima AM
J Clin Exp Hematop; 2023 Sep; 63(3):181-186. PubMed ID: 37518270
[TBL] [Abstract][Full Text] [Related]
4. Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis.
Ivanova VS; Davies J; Menter T; Wild D; Müller A; Krasniqi F; Stenner F; Papachristofilou A; Dirnhofer S; Tzankov A
Histopathology; 2024 Feb; 84(3):525-538. PubMed ID: 37965677
[TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets.
Agostinelli C; Morandi L; Righi S; Cirillo L; Iommi M; Tonon C; Mazzatenta D; Zoli M; Rossi M; Bagnato G; Broccoli A; Lodi R; Zinzani PL; Sabattini E; Giannini C; Asioli S
Mod Pathol; 2023 Dec; 36(12):100323. PubMed ID: 37678673
[TBL] [Abstract][Full Text] [Related]
6. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
Barton S; Hawkes EA; Wotherspoon A; Cunningham D
Oncologist; 2012; 17(12):1562-73. PubMed ID: 23086691
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.
Sarosiek KA; Nechushtan H; Lu X; Rosenblatt JD; Lossos IS
Br J Haematol; 2009 Nov; 147(3):308-18. PubMed ID: 19694722
[TBL] [Abstract][Full Text] [Related]
8. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
Lu X; Chen J; Sasmono RT; Hsi ED; Sarosiek KA; Tiganis T; Lossos IS
Mol Cell Biol; 2007 Mar; 27(6):2166-79. PubMed ID: 17210636
[TBL] [Abstract][Full Text] [Related]
9. Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.
Quentmeier H; Drexler HG; Hauer V; MacLeod RA; Pommerenke C; Uphoff CC; Zaborski M; Berglund M; Enblad G; Amini RM
PLoS One; 2016; 11(12):e0167599. PubMed ID: 27907212
[TBL] [Abstract][Full Text] [Related]
10. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Lenz G; Hawkes E; Verhoef G; Haioun C; Thye Lim S; Seog Heo D; Ardeshna K; Chong G; Haaber J; Shi W; Gorbatchevsky I; Lippert S; Hiemeyer F; Piraino P; Beckmann G; Peña C; Buvaylo V; Childs BH; Salles G
Leukemia; 2020 Aug; 34(8):2184-2197. PubMed ID: 32060403
[TBL] [Abstract][Full Text] [Related]
11. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.
Radotra BD; Parkhi M; Chatterjee D; Yadav BS; Ballari NR; Prakash G; Gupta SK
Surg Neurol Int; 2020; 11():424. PubMed ID: 33365186
[TBL] [Abstract][Full Text] [Related]
14. Fuzzy neural network applied to gene expression profiling for predicting the prognosis of diffuse large B-cell lymphoma.
Ando T; Suguro M; Hanai T; Kobayashi T; Honda H; Seto M
Jpn J Cancer Res; 2002 Nov; 93(11):1207-12. PubMed ID: 12460461
[TBL] [Abstract][Full Text] [Related]
15. Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies.
Xu PP; Sun C; Cao X; Zhao X; Dai HJ; Lu S; Guo JJ; Fu SJ; Liu YX; Li SC; Chen M; McCord R; Venstrom J; Szafer-Glusman E; Punnoose E; Kiermaier A; Cheng G; Zhao WL
EBioMedicine; 2018 Jul; 33():94-104. PubMed ID: 29936139
[TBL] [Abstract][Full Text] [Related]
16. Automatic subtyping of Diffuse Large B-cell Lymphomas (DLBCL): Raman-based genetic and metabolic classification.
Dawiec P; Leszczenko P; Nowakowska AM; Laskowska P; Szydłowski M; Juszczyński P; Baranska M; Mrówka P; Majzner K
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Mar; 309():123795. PubMed ID: 38184880
[TBL] [Abstract][Full Text] [Related]
17. A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.
Bethge N; Honne H; Andresen K; Hilden V; Trøen G; Liestøl K; Holte H; Delabie J; Lind GE; Smeland EB
PLoS One; 2014; 9(9):e104249. PubMed ID: 25226156
[TBL] [Abstract][Full Text] [Related]
18. Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype.
Dunleavy K; Roschewski M; Wilson WH
Clin Cancer Res; 2014 Oct; 20(20):5182-93. PubMed ID: 25320368
[TBL] [Abstract][Full Text] [Related]
19. Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.
Chiodin G; Allen JD; Bryant DJ; Rock P; Martino EA; Valle-Argos B; Duriez PJ; Watanabe Y; Henderson I; Blachly JS; McCann KJ; Strefford JC; Packham G; Geijtenbeek TBH; Figdor CG; Wright GW; Staudt LM; Burack R; Bowden TA; Crispin M; Stevenson FK; Forconi F
Blood; 2021 Oct; 138(17):1570-1582. PubMed ID: 34424958
[TBL] [Abstract][Full Text] [Related]
20. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma.
Fangazio M; Ladewig E; Gomez K; Garcia-Ibanez L; Kumar R; Teruya-Feldstein J; Rossi D; Filip I; Pan-Hammarström Q; Inghirami G; Boldorini R; Ott G; Staiger AM; Chapuy B; Gaidano G; Bhagat G; Basso K; Rabadan R; Pasqualucci L; Dalla-Favera R
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
